On September 23, 2026, Oppenheimer initiated coverage of Collegium Pharmaceutical (NASDAQGS: COLL) with an “Outperform” recommendation. Prior to this, the stock closed at $22.78 on September 22, 2026, marking a 4.30% increase over the previous week.
The current consensus target mean for the stock is $49.83, indicating a potential upside of 118.76% from current levels. Analyst sentiment remains positive with 12 recommendations, including 3 strong buy and 7 buy ratings as of September 1, 2026. In its last quarterly earnings report on August 6, 2026, Collegium posted an EPS of 1.92, exceeding estimates by 9.75%, with quarterly revenue recorded at $199.88 million.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
